VIDEO: Skyrizi induces clinical remission, endoscopic response in Crohn’s

VIDEO: Skyrizi induces clinical remission, endoscopic response in Crohn’s

In a video exclusive, Remo Panaccione, MD, University of Calgary, discusses his research showing Skyrizi bested placebo in inducing clinical remission in patients with Crohn’s disease.These results follow patients with moderate to severe CD who failed prior biologic treatment from the phase 3 MOTIVATE study. Patients received 600 mg or 1200 mg, of Skyrizi (risankizumab, AbbVie) or placebo at weeks 0, 4 and 8 and those that received the treatment drug showed greater rates of remission.“The exciting news for our field is that when you look at patients who had failed one biologicRead More

Share on facebook
Share on twitter
Share on linkedin